Monthly Archives: April 2020

Unified website for biotechnology regulation recently launched – Daily Herald

Posted on by

WASHINGTON, D.C. In recognition of National Biotechnology Month, the U.S. Department of Agriculture (USDA), the Food and Drug Administration (FDA) and the Environmental Protection Agency (EPA) recently launched a unified website for biotechnology regulation.

The website streamlines information about the three regulatory agencies charged with overseeing agriculture biotechnology products and is part President Donald J. Trumps Executive Order on Modernizing the Regulatory Framework for Agricultural Biotechnology Products.

Agricultural biotechnology has been and will continue to be an essential tool in helping Americas farmers and ranchers feed, fuel and clothe the world, said U.S. Secretary of Agriculture Sonny Perdue.

From producers to consumers, all Americans deserve a government that delivers science-based, common-sense regulations that foster innovation, conserve resources, and protect public healthespecially when it comes to the food supply, said Perdue.

The launch of this unified biotechnology regulation website is proof of President Trumps commitment to provide the American people with sensible regulations in a clear and transparent manner.

EPA is pleased to be working with our partners at USDA, FDA, and across the federal government to implement President Trumps Executive Order and launch this new, coordinated website, said EPA Administrator Wheeler.

This new website will help provide regulatory certainty and clarity to our nations farmers and producers by bringing together information on the full suite of actions the Trump Administration is taking to safely reduce unnecessary regulations and breakdown barriers for these biotechnology products in the marketplace, Wheeler said.

This is a time of unprecedented scientific innovation. Agricultural biotechnology promises to bring dynamic new products to the marketplace, said FDA Commissioner Stephen Hahn, M.D.

At the FDA, we are committed to fostering flexible, risk-based approaches in this field while upholding our mission of protecting and promoting both human and animal health and animal well-being, Hahn said.

For example, by reducing their susceptibility to diseases like novel influenzas and resistance to zoonotic or foreign animal diseases. Our approach balances our internationally respected, science-based review standards, Hahn said, with our ongoing risk-based regulatory approaches to ensure the safety of our food supply.

Background

The Unified Website for Biotechnology Regulation describes the federal review process for certain biotechnology products and allows users to submit questions to the three agencies.

The goals of this website are to provide enhanced customer service to innovators and developers, while ensuring Americans continue to enjoy the safest and most affordable food supply in the world and can learn more about the safe use of biotechnology innovations.

For more information, visit https://usbiotechnologyregulation.mrp.usda.gov/biotechnologygov/home/.

See the original post:
Unified website for biotechnology regulation recently launched - Daily Herald

Is bluebird bio Inc (BLUE) Stock Near the Top of the Biotechnology Industry? – InvestorsObserver

Posted on by

The 38 rating InvestorsObserver gives to bluebird bio Inc (BLUE) stock puts it near the bottom of the Biotechnology industry. In addition to scoring higher than 19 percent of stocks in the Biotechnology industry, BLUEs 38 overall rating means the stock scores better than 38 percent of all stocks.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

bluebird bio Inc (BLUE) stock is trading at $55.58 as of 1:27 PM on Friday, Apr 17, a gain of $3.02, or 5.75% from the previous closing price of $52.56. The stock has traded between $53.64 and $56.80 so far today. Volume today is high. So far 1,578,260 shares have traded compared to average volume of 1,164,930 shares.

To see the top 5 stocks in Biotechnology click here.

View post:
Is bluebird bio Inc (BLUE) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

Why genetics is key to the evolution of aquaculture – The Fish Site

Posted on by

Many species of fish and shellfish have been domesticated relatively recently compared with most livestock species, and so have diverse gene pools with major potential for selective breeding, according to a new review paper in Nature Reviews Genetics.

The development of tools to gain insight into the genetics of these species, and apply such tools for breeding and management, provides opportunities to release that potential, researchers say.

Most aquaculture species can produce many offspring, and large populations with improved genetics can be bred quickly for improved production performance.

The benefits may include improved growth, resistance to disease or robustness in diverse farming environments.

Farmed fish is on course to overtake wild fish as the main source of seafood, and consequently genetic tools and expertise are in high demand to increase the efficiency and sustainability of aquaculture systems, which currently rely mostly on unselected stocks.

Insight into the genomes of species can enable careful selection of a farming population with desirable traits, and monitoring genomic variation will help maintain genetic diversity as farm populations develop.

In the future, technologies such as genome editing could be used to introduce desirable traits, such as disease resistance, into farmed species, and surrogate breeding could be employed to support production of preferred species.

The review paper a collaboration between experts from Universities of Edinburgh, Exeter, Stirling, and Aberdeen is an output of the AquaLeap consortium project.

AquaLeap is funded by the Biotechnology and Biological Sciences Research Council, the Natural Environment Research Council and the Scottish Aquaculture Innovation Centre, in partnership with the Centre for Environment, Fisheries and Aquaculture Science, Hendrix Genetics, Xelect, The National Lobster Hatchery, Tethys oysters, and Otter Ferry SeaFish.

Environmental biologist Dr Eduarda Santos, from the University of Exeter, who is the co-author of the study, said: "The rapid expansion of aquaculture has contributed to increased food security across the globe, however, issues related to domestication of desired species and emergence of diseases, limit its further development.

"Genomics has the potential to offer solutions to many of these limitations by improving our knowledge of the genomes of cultured organisms, genetic selection, and better understanding of the dynamic interactions between genes and the environment, to maximise food production."

Dr Jamie Stevens, also from the University of Exeter and co-author added: "We only have to look at the example of Atlantic salmon to see the immense value of a sequenced genome to the relatively recent optimisation of a wild species for the aquaculture market.

"Similarly, we anticipate the delivery of a genome for other species, including the European lobster, will offer similar opportunities to develop molecular tools with which to rapidly increase the potential of lobster as an aquaculture species and improve the sustainability of its wild populations."

Professor Ross Houston, from the Roslin Institute, agreed, saying: "There is a timely opportunity to harness the potential of farmed aquatic species, to ensure food security for a growing population. Genomic selection and biotechnology can speed up this process, and recent developments in these fields will soon be translated to benefit aquaculture production for many of these species across the world."

Read more:
Why genetics is key to the evolution of aquaculture - The Fish Site

Investors should be cautious on the potential for Gilead’s drug Remdesivir, analysts say – CNBC

Posted on by

A new report from STAT News on Gilead's experimental drug Remdesivir serves as an encouraging update on the drug's potential to fight Covid-19, however analysts argue it's largely anecdotal and should be interpreted with caution.

Remdesivir was one of the first medicines identified as a contender to treat Covid-19 given it showed promise in the past in treating SARS and MERS, both caused by coronaviruses.

According to the report from an ongoing phase three trial at a University of Chicago hospital, patients showing severe Covid-19 symptoms who were given the drug saw rapid recoveries in fever and respiratory symptoms, with nearly all patients discharged in less than one week.

Gilead commented that, "the totality of the data need to be analysed in order to draw any conclusions from the trial," in a statement to Reuters. A statement from the University of Chicago Medicine said that "drawing any conclusions at this point is premature and scientifically unsound."

Jefferies equity analyst Michael J. Yee published in a research note that this Chicago report provides an "incremental positive" but he assumes this significant short-term move in Gilead's share price will probably pull back a bit given eventual broader awareness that this is not the actual phase three data and that this is overdone in the near term.

JPMorgan biotechnology equity analysts wrote in a published research note Thursday that "this clinical trial experience appears to represent another encouraging, albeit largely anecdotal, data point for this high-profile drug candidate."

Meanwhile, the Barclays health-care team called the update "encouraging" but note that questions persist.

The report from the Chicago hospital comes amid mounting anecdotal evidence supporting the drug's potential effectiveness in treating the virus. Last week, the New England Journal of Medicine published an analysis showing that two thirds of a small group of severely ill patients saw their condition improve after taking the drug. These patients were given Remdesivir as part of a compassionate use program which allows doctors to provide patients with unauthorized treatments when no other treatment is available.

There was no control group in the University of Chicago study. As CNBC's Meg Tirrell has highlighted, this is not controlled clinical trial data it is a glimpse into what one of the sites that is running the trial is seeing.

The information reported by STAT News came from an internal discussion among faculty members at a University of Chicago hospital captured on video, it was not official data released by Gilead or any other trial leader.

Furthermore, this data comes from a single trial site. The Barclays health-care equity research team wrote: "While these data are encouraging, they are uncontrolled and from a single center."

Jefferies echoes this point: "Similar to the NEJM publication last week, yesterday's reports are based on one site and there is no placebo."

There is also debate around the severity of the patients included in the study. This data is part of an ongoing phase three trial of patients with severe Covid-19 symptoms. However, the patients were not intubated to start the study. Barclays adds that there will be debate around the patient population and how they compare to past cohorts.

"There's still a great deal we don't know, and thus we hesitate to put too much into the results generated at a single center without a control group," said JPMorgan.

"Fortunately, we don't have to wait long for a Phase 3 readout in severe patients."

Gilead expects results from its trials with patients with severe Covid-19 later this month. Data from its trials on patients with moderate symptoms is expected in May.

In addition to these two trials being run by Gilead, there are several others underway concurrently to evaluate Remdesivir, including a phase two trial run by the National Institute of Health which is an adaptive, randomized, double-blind, placebo-controlled trial.

Barclays adds that data from Gilead's clinical trials on severe cases due at the end of this month could support approval or expanded use authorization. A treatment is not going to end the pandemic. But it will provide a critical bridge to the ultimate panacea a vaccine.

CNBC's Berkeley Lovelace contributed to this article.

View post:
Investors should be cautious on the potential for Gilead's drug Remdesivir, analysts say - CNBC

Is Inovio Pharmaceuticals Inc (INO) Stock Near the Top of the Biotechnology Industry? – InvestorsObserver

Posted on by

Inovio Pharmaceuticals Inc (INO) is near the top in its industry group according to InvestorsObserver. INO gets an overall rating of 72. That means it scores higher than 72 percent of stocks. Inovio Pharmaceuticals Inc gets a 83 rank in the Biotechnology industry. Biotechnology is number 6 out of 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Inovio Pharmaceuticals Inc (INO) stock has risen 8.82% while the S&P 500 is lower by -0.22% as of 10:32 AM on Thursday, Apr 16. INO is up $0.63 from the previous closing price of $7.14 on volume of 5,210,923 shares. Over the past year the S&P 500 is down -4.25% while INO is up 108.87%. INO lost -$1.21 per share the over the last 12 months.

To screen for more stocks like INO click here.

Read more:
Is Inovio Pharmaceuticals Inc (INO) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

$3.5 Bn Drug Discovery Informatics Market by Function, Solution, Application, End-user and Region – Forecast to 2025 – ResearchAndMarkets.com -…

Posted on by

DUBLIN--(BUSINESS WIRE)--The "Drug Discovery Informatics Market by Function (Target Data, Sequencing Data Analysis, Docking) Solution (Software, Services), Application (Drug Development), End User (Pharmaceutical, Biotechnology, Contract Research Organizations)-Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

The global drug discovery informatics market is projected to reach USD 3.5 billion in 2025 from USD 2.2 billion in 2020, at a CAGR of 9.3% during the forecast period.

Market growth is largely driven by factors such as the rising R&D expenditure, growing support for research, especially in the area of rare diseases, and the rising use of informatics in drug discovery. However, the scarcity of skilled professionals and the high setup cost of informatics software is expected to limit market growth to a certain extent.

The market study covers the drug discovery informatics market across various segments. It aims at estimating the market size and the growth potential of this market across different segments based on product, type of surgery, end user, and region. The study also includes an in-depth competitive analysis of the key players in the market, along with their company profiles, key observations related to their product and business offerings, recent developments, and key market strategies.

The major companies in the drug discovery informatics market include Jubilant Life Sciences Limited (India), Charles River Laboratories (US), IBM (US), Clarivate Analytics (US), and Accenture (Ireland). The study includes an in-depth competitive analysis of these key players in the drug discovery informatics market, along with their company profiles, recent developments, and key market strategies.

The sequence and target data analysis segment commanded the largest share of the market in 2019

On the basis of function the market is broadly segmented into sequencing and target data analysis, docking, molecular modeling, library & database preparation, and other functions. The sequencing and target data analysis segment accounted for the largest share of the drug discovery informatics market for the function segment of the market in 2019. The large share of this segment can be attributed to increased application for sequencing analysis for the new drug entity and ease of handling of information from different sources and different domains.

The software market dominated the market, by solution segment, in 2019

Based on solution the drug discovery informatics market is segmented into software and services. The large share of this segment is primarily attributed to the rising demand for new chemical entities due to the rise in new disease prevalence. The software helps eliminate the chance of drug failure, on a broad scope, and fulfills a wide range of other functionalities. This has ensured the demand for drug discovery informatics software among end-users.

The pharmaceutical companies segment commanded the largest share of the drug discovery informatics market in 2019

By the end-user, the drug discovery informatics market is segmented into pharmaceutical companies, biotechnology companies, contract research organizations (CROs) and other end users. The pharmaceutical companies segment accounted for the largest share of the market. The pharmaceutical companies segment accounted for the largest share of the drug discovery informatics market in 2019, pharmaceutical companies are using this informatics software extensively for pre-clinical research & development, target identification, compound screening and lead identification, and streamlining their drug discovery process which is the major factor for driving the growth of this segment.

The Asia-Pacific region to register the highest growth in the global drug discovery informatics market during the forecast period

The Asia-Pacific is estimated to grow at the highest CAGR during the forecast period. Factors such as the rapid growth in the pharmaceutical and biopharmaceutical industry, rising number of CROs, and the presence of less-stringent regulations for drug discovery processes

Key Topics Covered

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

4.1 Drug Discovery Informatics Market Overview

4.2 North America: Drug Discovery Informatics Market, by Solution and Country (2019)

4.3 Drug Discovery Informatics Market, by Function (USD Million)

4.4 Drug Discovery Informatics Market Share, by End-user, 2019

5 Market Overview

5.1 Introduction

5.2 Market Dynamics

5.2.1 Drivers

5.2.1.1 Increased Research Spending on Informatics by the Pharmaceutical and Biotechnology Industries

5.2.1.2 Growing Demand and Support for Rare Disease and Orphan Drug Research

5.2.1.3 Focus on Drug Discovery Using Informatics Software

5.2.2 Restraints

5.2.2.1 High Setup Costs of Informatics Software

5.2.3 Opportunities

5.2.3.1 Patent Expiry

5.2.3.2 Growing Biotechnology Industry and Biologics Market

5.2.3.3 Growth in Emerging Markets

5.2.4 Challenge

5.2.4.1 Dearth of Skilled Professionals

6 Drug Discovery Informatics Market, by Function

6.1 Introduction

6.2 Sequencing & Target Data Analysis

6.2.1 Sequencing & Target Data Analysis Holds Largest Share of the Market, by Function

6.3 Docking

6.3.1 Molecular Docking Targets the Development of Potential Molecules

6.4 Molecular Modeling

6.4.1 Capability to Generate Estimations of Drug Potential Make Modeling a Prominent Tool

6.5 Library & Database Preparation

6.5.1 Increase in Drug Research is Expanding the Use of Drug Databases

6.6 Other Functions

7 Drug Discovery Informatics Market, by Application

7.1 Introduction

7.2 Drug Development

7.2.1 Preclinical Testing

7.2.1.1 Growth in the Number of Preclinical Testing Activities to Support Market Growth

7.2.2 Clinical Trials

7.2.2.1 Informatics Software Help Assess Important Aspects About Clinical Trial Success

7.3 Drug Discovery

7.3.1 Increased Spending on Drug Discovery to Drive Market Growth

8 Drug Discovery Informatics Market, by Solution

8.1 Introduction

8.2 Software

8.2.1 Benefits of Informatics Software in Drug Discovery are Driving the Growth of the Market

8.3 Services

8.3.1 A Wide Range of Services is Available in the Market, from Installation to Post-Sales Support

9 Drug Discovery Informatics Market, by End-user

9.1 Introduction

9.2 Pharmaceutical Companies

9.2.1 Pharmaceutical Companies Accounted for the Largest Share of the Market in 2018

9.3 Biotechnology Companies

9.3.1 Increasing Demand for Personalized Medicine to Boost the Use of Informatics in Biotechnology Companies

9.4 Contract Research Organizations

9.4.1 Rise in Outsourcing to Drive the Growth of this End-user Segment

9.5 Other End-users

10 Drug Discovery Informatics Market, by Region

10.1 Introduction

10.2 North America

10.2.1 US

10.2.1.1 Rising R&D to Support the Growth of the Drug Discovery Informatics Market in the US

10.2.2 Canada

10.2.2.1 Presence of a Strong Pharmaceuticals Industry to Propel Market Growth in Canada

10.3 Europe

10.3.1 UK

10.3.1.1 the UK is the Largest Market for Drug Discovery Informatics in Europe

10.3.2 France

10.3.2.1 Loss of Patent Exclusivity of Biologics to Support the Growth of the Drug Discovery Informatics Market in France

10.3.3 Germany

10.3.3.1 Increasing Focus on Drug Discovery & Development to Drive Market Growth

10.3.4 Italy

10.3.4.1 High Production Volume to Boost Drug Informatics Growth

10.3.5 Spain

10.3.5.1 Rising R&D Expenditure to Drive Market Growth in Spain

10.3.6 Rest of Europe

10.4 Asia-Pacific

10.4.1 China

10.4.1.1 Large R&D Pharmaceutical Footprint to Drive Market Growth in China

10.4.2 India

10.4.2.1 Presence of a Large Number of Cros in India to Propel Market Growth

10.4.3 Japan

10.4.3.1 Rising Government Initiatives for Drug Discovery to Support the Adoption of Informatics Software in Japan

10.4.4 Rest of Asia-Pacific

10.5 RoW

See the original post:
$3.5 Bn Drug Discovery Informatics Market by Function, Solution, Application, End-user and Region - Forecast to 2025 - ResearchAndMarkets.com -...

Aptamers Market Business intelligence Report and financial Insights. Top Companies are TriLink BioTechnologies, LLC, Vivonics Inc., NOXXON Pharma,…

Posted on by

The Aptamers Market report offers a complete and intelligent analysis of the competition, segmentation, dynamics, and geographical advancement of the global Aptamers market. The market report is sure to lend a hand in enhancing sales and improving return on investment (ROI). This market research report provides clients with the supreme level of market data and information which is specific to their niche and their business requirements. This global Aptamers market research report is a proven source to gain valuable market insights and take better decisions about the important business strategies.

Request for sample copy or PDF Here https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-digital-health-technologies-market

Global Aptamers Marketis expected to rise from its initial estimated value of USD 176.86 million in 2018 to an estimated value of USD 722.69 million by 2026, registering a CAGR of 19.01% in the forecast period of 2019-2026. This rise in market value can be attributed to the increasing R&D investments in biotechnology and pharmaceutical sectors.

Few of the major competitors currently working in the globalaptamers marketareAptamer Sciences, Inc., AMBiotech, Aptagen, LLC., Aptamer Group, Aptus Biotech, Base Pair Biotechnologies, Cambio, NeoVentures Biotechnology Inc., SOMALOGIC, INC., TriLink BioTechnologies, LLC, Vivonics Inc., NOXXON Pharma, 2bind GmbH, NOVAPTECH, Donovan Biotechnology, LLC, ATDBio Ltd., AuramerBio, Barrick Lab, Creative Biogene, AMS Biotechnology (Europe) Limited, IBA GmbH and Kaneka Corporation among others.

Market Definition: Global Aptamers Market

Aptamersare single-stranded DNA or RNA (ssDNA or ssRNA) molecules. Aptamers are the oligonucleotide or peptide molecules that bind to a specific target molecule. It assumes to have a variety of shapes due to their tendency to form helices and single-stranded loops. There are many advantages of these small molecules in comparison to the antibodies.

Technology market research report are based upon SWOT analysis on which businesses can rely confidently.

Segmentation: Global Aptamers Market

Aptamers Market : By Type

Aptamers Market : By Application

Aptamers Market : By Technology

Aptamers Market : By End User

Aptamers Market : ByGeography

Browse Detailed TOC Herehttps://www.databridgemarketresearch.com/toc?dbmr=global-aptamers-market

Key Developments in the Aptamers Market:

Aptamers Market Drivers

Aptamers Market Restraints

Aptamers Market : Competitive Analysis

Global aptamers market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of global aptamers market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Primary Respondents

Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.

Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.

Features mentioned in the report

Want Full Report? Enquire Herehttps://www.databridgemarketresearch.com/inquire-before-buying?dbmr=global-aptamers-market

About Data Bridge Market Research:

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475 Mail:[emailprotected]

More:
Aptamers Market Business intelligence Report and financial Insights. Top Companies are TriLink BioTechnologies, LLC, Vivonics Inc., NOXXON Pharma,...

This Anti-Aging Facial Tool Instantly Firms and Lifts Skin and It’s Half Off – Yahoo Lifestyle

Posted on by

If youre as beauty obsessed as I am, then you most likely have an infinite number of reasons to justify the (not so) occasional skincare splurge. Perhaps youve exhausted the products in your daily regimen, or youve begun to notice unwelcome changes to your complexion that need a little boost beyond your favorite eye cream. While regular visits to the dermatologist may not be an option for most, at-home beauty devices very well can be. And since many of these tempting tools can still err on the pricey side, it helps to keep an eye out for the occasional sale (wink, wink).

Raffaele Ruberto R-Lift X-Calibur Firming and Contouring Device is a micro-massaging device that delivers a more youthful complexion instantly, and it happens to be 50 percent off at Nordstrom right now. The sleek anti-aging tool firms and lifts the skin, particularly around the eyes, neck, and cheek bones. Just turn the device on and glide the t-bar head effortlessly across your skin for 10 minutes, letting the micro-currents do their work.

This device can be the perfect handy tool before any major event or your everyday makeup application, giving you plump, healthy-looking skin in minutes. You can also run it across both your top and bottom lips for a temporary plumping effect. Since the tool claims it provides an immediate difference in the lift and plumpness of skin, it left us curious what wonders this device can do after consistent daily use, so we turned to some Nordstrom shoppers to fill us in.

I incorporated the device into my serum routine and it immediately showed results by evening out my skin tone and texture, tightening and firming my skin, and helping with my pores, writes one shopper. Its definitely an investment. If youre spending $$$ using high-end beauty products, this device will elevate the return. I am a fan.

RELATED: This Anti-Stress Serum Is Here to Rescue Your Skin From Worry Lines and Uneven Texture

Another says, I have every tool in the industry and this is a game changer! I'm already obsessed with this brand's No. 9 R-lift face and eye serum, which gives me that glass-like finish every time I put it on...but this tool, gives me an instant lift around my entire face and jawline, and plumps my lips! I always put my skincare on first then use this for increased penetration. I swear after two weeks, its taken my skin to the next level!

While the beauty tool normally goes for $125 dollars, weve caught it just in time for a major discount. For even better results, pair the firming and contouring device with the brands own face and eye serum, alongside the neck and decollete serum.

Read the original here:
This Anti-Aging Facial Tool Instantly Firms and Lifts Skin and It's Half Off - Yahoo Lifestyle

Medical Wellness Market Report (2020-2027) on the basis of proprietary technologies, distribution channels, industrial penetration, manufacturing…

Posted on by

(MENAFN - iCrowdNewsWire) Apr 17, 2020

The Medical Wellness market research report is now available at Market Expertz is an extensive sketch of the business sphere in terms of present and future trends driving the profit matrix. The study also mentions a pointwise outline of the Medical Wellness market share, market size, industry manufacturers, and regional landscape supported with detailed statistics, diagrams, & charts throwing light on the various noteworthy parameters of the industry landscape.

The report includes the latest coverage of the impact of COVID-19 on the Medical Wellness industry. The incidence has affected nearly every aspect of the business domain. This study evaluates the current scenario and predicts future outcomes of the pandemic on the global economy.

Request a sample Report of the Medical Wellness [email protected] https://www.marketexpertz.com/sample-enquiry-form/101491

The report provides reliable data regarding key investment pockets in the Medical Wellness market, along with the growth pattern followed by the industry over the forecast period. Moreover, the report also focuses on the threats and growth prospects present in the industry, which are speculated to dictate industry growth in the coming years.

Leading Medical Wellness manufacturers/companies operating at both regional and global levels:

Steiner Leisure LimitedWorld GymFitness WorldUniversal CompaniesBeauty FarmVLCC Wellness CenterNanjing ZhaohuiEdge Systems LLCHEALING HOTELS OF THE WORLDGold's Gym InternationalBon VitalKaya Skin ClinicThe Body HolidayKayco VividArashiyu Japanese Foot SpaEnrich Hair & SkinWTS InternationalBiologique RechercheGuardian LifecareHealthkart

The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.

Competitive Landscape:

It provides an exhaustive examination of the industry and contains valuable insights in the context of essential parameters of the business sphere. It contains important details about the market share, the latest industry trends, market size, periodic deliverables, and price projections over the forecast period.

Order Your Copy Now (Customized report delivered as per your specific requirement) @ https://www.marketexpertz.com/checkout-form/101491

The segmentation included in the report is beneficial for readers to capitalize on the selection of appropriate segments for the Medical Wellness sector and can help companies in deciphering the optimum business move to reach their desired business goals.

In market segmentation by types of Medical Wellness, the report covers-

Complementary and Alternative MedicineBeauty Care and Anti-AgingPreventative & Personalized Medicine and Public HealthHealthy Eating, Nutrition & Weight LossRejuvenationOther

Top pointers listed in the Medical Wellness market report:

In market segmentation by applications of the Medical Wellness, the report covers the following uses-

FranchiseCompany Owned Outlets

Industry Insights in the report:

To get in-depth insights into the global Medical Wellness market, reach out to us @ https://www.marketexpertz.com/customization-form/101491

Geographical hierarchy of the Medical Wellness markets:

Medical Wellness Market segmentation:

Key Coverage of Report:

For More Details on this Report, [email protected] https://www.marketexpertz.com/industry-overview/global-2020-medical-wellness-market

Major Highlights of the TOC are:

Medical Wellness Regional Market Analysis

Analysis of Medical Wellness market by Type

Analysis of Medical Wellness market by Application

Medical Wellness Major Manufacturers Analysis

Get Your Copy at Discounted [email protected] https://www.marketexpertz.com/discount-enquiry-form/101491

To summarize , the global Medical Wellness market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

Contact Us:John WatsonHead of Business Development40 Wall St. 28th floor New York CityNY 10005 United StatesMarket Expertz | Web: http://www.marketexpertz.comDirect Line: 1-800-819-3052E-mail: [email protected]

MENAFN1804202000703403ID1100043879

Continue reading here:
Medical Wellness Market Report (2020-2027) on the basis of proprietary technologies, distribution channels, industrial penetration, manufacturing...

Celebrity skin gurus share their best skincare tips and products – New York Post

Posted on by

Instead of a cooped-up quarantine, think of this as a self-care staycation. What better time to commit to a skincare overhaul?

We asked Lady Gagas skin expert Ada Ooi, along with celebrity aestheticians Vicki Morav (who works her magic on Kyra Sedgwick) and Mimi Luzon (skin savior to Gigi and Bella Hadid), to weigh in with their best skincare advice, routines and brands.

If you follow their expert tips, you may actually emerge from this anxiety-ridden time looking refreshed. (Or at least distract yourself in the meantime.)

London-based Ooi whose Traditional Chinese Medicine (TCM) techniques are beloved by Mother Monster, Kate Middleton, Ellie Goulding and Rooney Mara (to name a few of her famous clients) recommends massaging your face with oil while youre #stayinghome.

It may seem counterintuitive, but she says the strategy will balance stressed skin and prevent pesky pimples and blackheads.

A lot of my customers with acne dont realize that the excessive sebum or blocked pores are actually created by their skin layers being too dry and sending a wrong signal to the brain that the skin needs more oil, she explains. Oil attracts oil, oil melts oil, and a good face oil with small oil molecules doesnt clog pores.

Our pick? This reparative product by Skyn Iceland, composed of 99.9% camelina oil, which is rich in fatty acids, antioxidants and anti-inflammatories.

Skyn IcelandArctic face oil, $42 at Dermstore

Ooi also suggests moisturizing your skin with a pro-level serum. A pea-size drop of Alpha Glow Flash Facial a three-in-one serum, primer and mask from her cult-favorite 001 Skincare line works like a spa visit in a bottle.

Its nine powerhouse ingredients, including hyaluronic acids, phospholipids, aloe vera and rose extracts, perk up dull and dry skin and aid in optimal water retention.

It also contains a low dose of salicylic acid and retinyl palmitate for breaking down stubborn sebum and providing gentle exfoliation, Ooi tells The Post.

Alpha-Glow Flash Facial, $144 (50 ml) at 001 Skincare

One essential to add to your sunlit WFH office space? SPF.

While glass used in cars and home windows are usually designed to block most UVB rays long-length UV that directly damages DNA and skin cells it does not offer protection from all UVA rays shorter-length UV that can contribute to skin-cell aging, leading to wrinkles and sunspots, explains Ooi. If youre indoors sitting close to a window you still run the risk of exposure to UVA rays and possible skin damage.

Our sunscreen loyalty lies with Supergoop! Zincscreen, a lightweight, pink-hued and non-nano zinc oxide formula composed of winter cherry, coconut and blueberry extracts.

Luxury lovers should opt for Mila Moursis broad spectrum sunscreen SPF 30, an antioxidant-packed gel with a splurge-worthy silky matte finish that doubles as a makeup primer.

Supergoop! Zincscreen SPF 40, $42 at Nordstrom

Broad spectrum sunscreen SPF 30, $148 at Mila Moursi

If youve tried every over-the-counter or derm-approved medication for troublesome cystic breakouts and still cant find relief, Ooi suggests trying LED light therapy. This powerful, noninvasive treatment triggers your bodys natural cell processes to accelerate skin rejuvenation, destroy acne-causing bacteria and eliminate scars.

I recommend starting with a blue light, which targets overactive oil glands and kills acne-causing bacteria beneath the skin, followed with a red light, she says. Once the epidermis absorbs the red light, it stimulates collagen protein growth to help scars heal, reduce inflammation and improve circulation leading to more oxygen and nutrients to speed up recovery.

Achieve similar results with Dr. Dennis Gross Skincares #stayhome version. The Darth Vader-like contraption calms inflammation, reduces wrinkles and eliminates sun spots, all while you lounge on the couch.

Dr. Dennis Gross Skincare SpectraLite FaceWare Pro, $435 at Dermstore

Jade rollers are so 2019. This years millennial must-have is a gua sha gadget (based on a 2,000-year-old Chinese technique) which promises to improve nearly every skin affliction, from rosacea to adult acne.

Its one of the easiest ways to boost micro-circulation, says Ooi. More blood circulating to the skin means more oxygen delivery, which rids toxins and excessive fluids that might be creating unnecessary weight in combination with gravity.

Snag this therapeutic massage tool with your next Sephora order to reduce fine lines (including marionette and nasolabial laugh lines) for a better-than-Botox effect.

Mount Lai gua sha tool, $34 at Sephora

Your routine must begin (and end) with a clean canvas, so choose a daily cleanser that will remove dirt, leftover makeup, sweat and dead skin cells without drying you out.

New York-based expert Morav, whose Upper East Side spa draws celebs such as Sedgwick, Kevin Bacon and Kelly Rutherford, agrees: Cleansing is one of the most important starters during the skincare regimen, she tells The Post. My favorites are Forlled creamy foam for deep cleansing but not stripping, MBR enzyme booster for a mild to deep exfoliation, and Valmont White Falls for a creamy and gentle experience for sensitive skin.

Forlled Hyalogy creamy wash, $86 (148 ml) at Vicki Morav

MBR Medical Beauty Research enzyme cleansing booster, $227 (83 ml) at Vicki Morav

Valmont White Falls cleanser, $75 (124 ml) at Vicki Morav

If you already have an eye cream in your beauty arsenal, enlist it for double duty to perk up your pout. We can treat lips [the same way] we treat the areas around the eyes, says Morav. The skin has no oil glands, so it really depends on everything we put around it and on it.

Dab your go-to eye potion around your mouth and lips twice a day to hydrate and smooth fine lines.

Our hero product is Sisley-Paris eye contour mask: Work it into your lips to improvise a Kylie Jenner-inspired pucker before your next virtual date.

For extra kiss-worthy lips, add another layer of regenerating balm. Moravs pick is Perfect LipID from MBR.

Sisley-Paris eye contour mask, $149 at Saks Fifth Avenue

MBR Medical Beauty Research Perfect LipID balm, $102 at Vicki Morav

Yes, you can emerge from quarantine with a supermodel glow. This Irina Shayk-approved gold-leaf mask by Luzon (facialist to the Hadid sisters and many a Victorias Secret Angel) leaves skin radiating for more than a week.

Our 24-k gold mask is very popular among A-list celebs as it gives an instant glow to the skin that is visible in the eye for at least 10 days, Luzon tells The Post. This means that it is a real treatment, not just a beauty treatment.

24-k pure gold treatment, $149 (for one treatment), at Mimi Luzon

24-k pure gold treatment, $349 (for four treatments) at Mimi Luzon

For more quarantine skincare tips, check out our chat with celebrity makeup artistSheika Daley, whos spent years perfecting the complexions of Zendaya, Beyonc, Kelly Rowland and La La Anthony.

Visit link:
Celebrity skin gurus share their best skincare tips and products - New York Post

The Skincare World Is Obsessed With Hyaluronic Acid – Yahoo Lifestyle

Posted on by

Photo credit: Getty Images

From Good Housekeeping

In the skincare world, buzzy ingredients are a dime a dozen. But the super-trendy ingredient hyaluronic acid (HA) is actually here to stay. It's a powerhouse hydrator that's safe for virtually all skin types and can be found in everything from eye cream to face serum. But what is hyaluronic acid? "Naturally produced in the human body, [hyaluronic acid] is type of a sugar molecule that keeps our tissues cushioned and lubricated," explains Birnur Aral, Ph.D., director of the Good Housekeeping Institute Beauty Lab. "It is found in skin, joints, and connective tissue."

Don't be intimidated by the word "acid" in its name: Unlike exfoliating alpha- and beta- hydroxy acids or salicylic acid, HA is actually a gentle hydrator. In fact, when it's formulated for skincare, "hyaluronic acid is like a sponge that finds up to 1,000 times its weight in water," says Joshua Zeichner, M.D., director of cosmetic and clinical research in dermatology at Mount Sinai Hospital in New York City. "It is what gives the skin its plumpness."

Skincare products with HA work hard to bring moisture to your skin all day by consistently drawing hydration from the air into your skin. In Beauty Lab tests, we've found that products with hyaluronic acid can hydrate skin extremely efficiently: Sometimes 400% better than creams 18 times the price, as we saw with Olay Regenerist Micro-Sculpting Cream. Here's what HA is best at:

Hydrating. "Hyaluronic acid is a skin plumper by way of its ability to retain moisture," says Brendan Camp, M.D., double board-certified dermatologist and dermatopathologist at Medical Dermatology & Cosmetic Surgery in New York City. "It helps to hydrate dry skin, providing a smooth, soft appearance."

Anti-aging. "As we age our skin produces less HA, contributing to the appearance of wrinkles," Dr. Camp explains. Hyaluronic acid hydrates and plumps skin to "improve the appearance of fine lines and wrinkles," says Dr. Zeichner.

Joint pain. Yes, really but not applied topically. "Hyaluronic acid injections are also given to joints of people suffering from arthritis," says Aral. HA supplements are also popular for those suffering from joint pain and osteopenia.

Story continues

"Hyaluronic acid is something your body naturally makes, so it is generally considered safe [for all skin types]," says Dr. Camp. Allergic reactions to HA are rare, so that means whether you have oily skin, sensitive, dry skin, or combination skin, you have the green light to use hyaluronic acid products. Our pros note that HA is particularly helpful for parched skin in need of deep hydration.

"Because it works by retaining skin moisture, [HA] is most often found in products that are left on the skin," says Dr. Camp. "It can be found in face creams, serums, masks, eye creams, and body lotions." Even on sensitive skin, "it can be used twice daily," says Dr. Zeichner. "If you are dry, I typically recommend it as a serum under your moisturizer." Keep in mind that your favorite skincare products might already be laced with hyaluronic acid: Check the label for mention of "sodium hyaluronate."

If you feel that your fine lines and sallowness are too much for topical skincare products to tackle, keep in mind that "hyaluronic acid is the ingredient in fillers like Juvderm and Restylane that are used to volumize the skin," says Dr. Camp. Put simply, the injectable form of HA smooths out skin by increasing the volume in lips, cheeks, or any other area that may be prone to signs of aging, says Aral. These injections are temporary and will be broken down by enzymes in the body in six months to a year's time.

You Might Also Like

Read more from the original source:
The Skincare World Is Obsessed With Hyaluronic Acid - Yahoo Lifestyle

Discovery links glucose metabolism abnormalities to Alzheimer’s disease – New Atlas

Posted on by

A new study, funded by the National Institutes of Healths National Institute on Aging, is offering novel insights into how protein expressions can be altered during the course of Alzheimers disease. The research suggests proteins regulating glucose metabolism and the anti-inflammatory activity of brain immune cells are linked with Alzheimers pathology, and could point researchers toward new treatment and diagnostics.

The study, published in the journal Nature Medicine, comes out of a larger project called the Accelerating Medicines Partnership for Alzheimers Disease (AMP-AD). This NIH-led venture is designed to advance novel diagnostic and treatment targets while bringing together government, industry, and nonprofit organizations.

This new paper describes the results of the largest Alzheimers-related protein study conducted to date, gathering over 2000 brain tissue samples and around 400 cerebrospinal fluid samples from research centers across the United States. Expression patterns of more than 3000 proteins were measured, looking at differences between healthy subjects and Alzheimers patients at different stages of the disease.

This large, comparative proteomic study points to massive changes across many biological processes in Alzheimers and offers new insights into the role of brain energy metabolism and neuroinflammation in the disease process, explains Suzana Petanceska, the NIA director managing the AMP-AD Target Discovery Program.

In both cerebrospinal fluid and brain tissue samples the research revealed higher expressions in Alzheimers patients of proteins involved in glucose metabolism and anti-inflammatory processes. Importantly, these elevated protein levels were also detected in subjects with preclinical Alzheimers, suggesting as well as a potential new treatment target, the protein abnormalities could serve as an effective early-stage biomarker of the disease.

Weve been studying the possible links between abnormalities in the way the brain metabolizes glucose and Alzheimers-related changes for a while now, say Madhav Thambisetty, one of the authors on the new study. The latest analysis suggests that these proteins may also have potential as fluid biomarkers to detect the presence of early disease.

The researchers note this study describes what is known as a fundamental research finding. This essentially means the study is outlining a foundational discovery, from which future research will hopefully be able to build new treatments or diagnostics. Suzana Petanceska notes this work has already been spread around the Alzheimers research community with the goal of inspiring new treatment targets.

The data and analyses from this study has already been made available to the research community and can be used as a rich source of new targets for the treatment and prevention of Alzheimers or serve as the foundation for developing fluid biomarkers, she concludes.

The study was published in the journal Nature Medicine.

Source: NIH

Continue reading here:
Discovery links glucose metabolism abnormalities to Alzheimer's disease - New Atlas

COVID-19 is Not Really a Pandemic as Pandemics Go – Live Trading News

Posted on by

it is a Power, Profit, Control Pandemic.

The economic collapse is a result of precisely engineered governmental policies though those policies appear to be in the publics best interest.

COVID-19 meets the technical definition of apandemic, and the World Health Organization (WHO) declare it so. However, the death toll is nowhere near that of real pandemics that would legitimately justify the extraordinary measures being deployed by the US and some other 1st world government.

The Spanish flu in Y 1918 infected 500-M people worldwide, killing between 20 and 50-M. The Bubonic plague killed 50-M people, wiping out 60% of the European population. Those are what people think of when they hear the word pandemic.

COVID-19 presently affects a ultra-tiny fraction of the global population about 1.4-M cases out of a global population of 7.78-B, and even with a death toll of 81,000 worldwide, COVID-19 has had a miniscule impact, having killed a only 0.00001% of the population.

Death is inevitable, but any given individuals risk of dying from the epidemics ofdiabetes,heart diseaseorcancer, for example, is greater than their risk of dying from COVID-19 coronavirus.

Death seems to be acceptable from poor lifestyle-induced disease and environmental toxicity.

The Big Q: Why is it preferable and acceptable than death from an infectious disease?

Also, dying from a preventable medical mistake is a far greater risk, as thatkills up to 440,000 Americans every year.

The Big Q2+: Where is the panic about that? Is not the notion that conventional medicine kills 440,000 people a year terrifying? And 20% elderly patients are also injured by medical care. Where are the calls to protect our aging loved ones from this threat?

Were health policies more aligned with truth, we would not have these chronic disease epidemics and far fewer people would die from preventable medical mistakes.

More people must learn lead healthy lives, the need to be properly informed and take to heart what is harmful and what is healthy.

What I have learned over these past 5 wks is that when it comes to COVID-19, there are simple strategies with which people can address infection that does not require collapsing the global economy, creating unheard of unemployment and isolating everyone from human contact for wks on end. You can find many articles detailing such strategies in our coronavirus archive here

One size does not fit all situations and this knowledge has not been applied in this pandemic. What has been wrongly applied here is that everyone is being treated as though they are high risk for severe infection and death and therefore need to take identical precautions.

The Big Q3: What is happening here?

The Big A3: Shiva Ayyadurai, PhD in systems biology from MIT tell us: We have not said, Hey, lets shut down the economy to address the fact that we have skyrocketing obesity taking place, skyrocketing diabetes. So, the level of contradiction, the level of hypocrisy should wake up everyone to understand that there is another agenda.

There is another agenda afoot. I repeat what my mentor said: When things do not add up, take a step back and ask, what is the other agenda? And the only thing in a common-sense way that reveals itself to me is power, profit and control. Power, Profit and Control.

I believe that fear mongering is being used to suppress dissent, to crash the economy and to issue medical mandates, as does Dr.Ayyadurai. If you look broadly, there were massive uprisings, anti establishment uprisings in different countries. Well, they are all gone now. We do not even hear anything about them, Dr. Ayyadurai says.

He also believes this fearmongering and social isolation mandates will be used as a way to acclimatize people to accept state wants or what a few people deem is good for everyone.

A group of enlightened people tried that in the 1800s and failed, have they come alive and at it again?

That, I think, is the milieu being set up, he says. Theres another agenda,Dr. Ayyadurai says. Thats what I see, because it does not make any rational sense to crash the world economy over COVID-19. And to everyday working people, it does not make sense either. They are trying to sort this out.

In Summary: The 3-pronged agenda is; Power, Profit and Control. To counteract that threat, we need academic freedom and the freedom to discourse and debate. From that freedom, truth, and from truth, we are able to understand health, not only physical health but also in the broadest sense the health of our systems, our infrastructure and environment. With health, we gain the strength to fight for more freedom.

Freedom to manage The Fourth Industrial Revolution, and part of that management is to decentralize healthcare.

Have a healthy weekend, Keep the Faith!

control, coronavirus, COVID-19, death, disease, economy, freedom, health, lifestyle, pandemic, power, revolution, risk, Shiva Ayyadurai, strength, systems, truth, WHO, world

Paul A. Ebeling, polymath, excels in diverse fields of knowledge. Pattern Recognition Analyst in Equities, Commodities and Foreign Exchange and author of The Red Roadmasters Technical Report on the US Major Market Indices, a highly regarded, weekly financial market letter, he is also a philosopher, issuing insights on a wide range of subjects to a following of over 250,000 cohorts. An international audience of opinion makers, business leaders, and global organizations recognizes Ebeling as an expert.

Here is the original post:
COVID-19 is Not Really a Pandemic as Pandemics Go - Live Trading News

5 best herbal teas for burnout – Thrive Global

Posted on by

Burnout and tiredness

Tired, stressed, feeling on the edge of burnout? Youre not the only one. Burnout has become so common in society today. It is due to the modern ever-running lifestyle that the majority of us live in.

Why do you feel tired? Indeed, during burn out the adrenal glands become depleted. They are not secreting adequate hormones to function properly (Sarah Powell). Thats why, if not treated, you can find yourself in long term effects. These are such as insomnia, depression, weight gain, and lowered immunity.

Well, the mechanism of adrenal fatigue and burnout is understood. What you can do about it?

There is a simple & natural cure that you might neglect. A good herbal tea!

The benefits of herbal teas to our well-being have been long known. Many studies reclaimed these. Herbal teas can help to lower cortisol levels. Increase the production of mood-enhancing hormones like GABA (gamma-aminobutyric acid), and dopamine. Thereby helping you to feel calmer and less anxious (Adrenal Fatigue Coach).

A word of caution: Herbal tea cannot replace a medical cure. Yet it can definitely bring natural calming effects and relaxation. It helps you unwind from a busy and tiring day.

Well, you can find quite readily available herbal teas on most supermarkets and food stores. They are also available online. Its quite easy to find. However, a good herbal tea purchase needs some considerations.

Herbal teas are not medicine. They thus arent regulated by theFDAand other regulators. So a trustworthy source is always a common sense. Have a tea infuser? Whole leaf teas are good in this case.Like to grow your own herbs? That would be for sure an enjoyable way to have a secure source of tea.

Although some herbal teas are highly safe to drink, some might interact with other treatments. Consider your pregnancy or known medical conditions/allergies. Talk with your doctor before taking a new type of herbs. Its always a good idea. Also,most herbal teas are safe to consume in regular but small amounts. But it is important not to go overboardat once.

The final consideration is, of course, which herbs to choose for your tea.

Need help dealing with burnout, anxiety, and insomnia? My best choices for herbal teas would be rooibos, caffeine-reduced green tea, chamomile, ginger, and licorice. Drink these calming teas. Breath their soothing scent. Practice relaxation techniques such as meditation and yoga. They can help you wind down in stressful periods.

Rooibos tea is made from a plant called Aspalathus linearis. It grows only in South Africa. The red rooibos tea that we usually see is the fermented tea. Its considered the best herbal tea in the world. It is caffeine-free, full of antioxidants and extremely safe to drink. It has a lot of beneficial substances such asaspalathin and nothofagin. They provide extraordinary health benefits. These include calming, skin and anti-aging benefits. Rooibos tea alsoblends perfectly with many other ingredients.

The only thing to be aware of is that green tea can have caffeine. This can prevent sleep if you drink in the evening.Therefore, my choice would be for a low percentage of caffeine green tea. And drink them in the morning!

Chamomile tea one of the most popular calming teas. It is easily accessible. A famous bedtime tea, for its relaxation effect and sleep improvement.Researchersfound that chamomile use showed a significant decrease in anxiety symptoms. Indeed, chamomile tea contains apigeninan antioxidant that directly targets neurotransmitters and brain receptors to induce relaxation (Very Well Mind). A pilot study (published in BMC Complementary and Alternative Medicine in 2011) also showed its effect on insomnia reduction.

Im Asian. Thats how ginger has been part of my childhood, in all of our family cooking recipes. Ginger has long since been used throughout Asia and the wider world. (Attention, ginger tea is different from ginseng tea, another plant)Researchshowed a positive health impact of ginger.Ginger tea has calming properties that may help lower your stress and tension. This is thought to be due to a combination of the strong aroma and healing properties. Therefore, in a burnout state, ginger can help reduce the feeling of stress and depression.

Whether to choose it or not? You will need to taste it. Ginger tea has a slightly bitter and invigorating flavor which is not the case of a gentle chamomille or rooibos teas. Also, as ginger benefit during pregnancy is controversial, dont hesitate to consult your doctor.

Finally, we cant forget Licorice tea!David Hoffman, Englands premier herbalist, recommended it for the adrenal cortex (what produces the stress hormone cortisol). So you know, its beneficial for stress reduction.A 2013studyfound that licorice extract may also increase the effects of anti-anxiety medications. A word of caution: If you are taking medications to treat anxiety, always talk to your doctor before trying a new herbal supplement or remedy.

In burnout, untreated stress and fatigue can lead to long term effects. These are such as insomnia, depression, weight gain, and lowered immunity. A simple & natural cure that you might neglect is a good herbal tea. Among those, rooibos, chamomile, green tea, ginger, and licorice are the most popular teas. They are great for relaxation, stress and fatigue relief.

I used to buy those very nice teas as gifts to friends and family during special occasions. Since my burnout, I decided that I merited them as well. I take care and love myself as I do to my beloved one. And I have to say, these royal herbal teas brought me sweet comforting moments. Try them and find out which one you prefer.

Read more

Visit link:
5 best herbal teas for burnout - Thrive Global

University of Waterloo researchers developing non-invasive COVID-19 vaccine – Toronto Sun

Posted on by

A new, non-invasive COVID-19 vaccine is being developed by researchers at the University of Waterloo.

The DNA-based vaccine will be delivered as a nasal spray and have both preventative and therapeutic effect.

Dr. Roderick Slavcev, a professor in the School of Pharmacy, explained Wednesday that the vaccine uses bacteriophage the process allows the vaccine to replicate within bacteria already in the body and is being designed to target tissues in the nasal cavity and lower respiratory tract.

Once complete, our DNA-based vaccine delivers nanomedicine engineered to immunize and decrease COVID-19 infections, said Slavcev, who specializes in designing vaccines, pharmaceuticals and gene-therapy treatments.

The genetic cargo to be delivered attaches to receptors in the respiratory tract, where COVID-19 would attach so its competing for the same spots.

Dr. Roderick Slavcev, a professor in the UW School of Pharmacy.

The DNA vaccine, he adds, will both stimulate an immune response, firing up the bodys capacity to fight off COVID-19, and also prevent further infection.

The vaccine enters cells in targeted tissues and causes them to produce a virus-like particle (VLP) that will stimulate an immune response.

The VLP will look similar to the structure of SARS-CoV-2 the virus which causes COVID-19 but is harmless. However, the similarity activates the bodys natural immune response to protect against viral infections comparable to the VLP, including SARS-CoV-2. In binding to the same receptors that SARS-CoV-2 would bind to, it limits possible sites for transmission.

In this way, the vaccine can build immunity against COVID-19 and decrease the severity of infections in progress, working as a therapeutic and a vaccine.

Said Slavcev, Its a cool way to mimic a virus for maximal protection.

Slavcev is teaming up with Emmanuel Ho, another professor at the School of Pharmacy, and Marc Aucoin, professor of chemical engineering.

Hos team is designing the nanomedication that will be delivered by the nasal spray, which is currently being tested. Aucoins lab is constructing and purifying the VLP and boosting immunity following the initial administration of the therapeutic vaccine.

Asked for a time line, Slavcev said, We are expediting quickly. We anticipate going to animal trials within six months and hope to have completed them by May of 2021.

lbraun@postmedia.com

Continue reading here:
University of Waterloo researchers developing non-invasive COVID-19 vaccine - Toronto Sun

Mark Cuban and Tyler Winklevoss Squabble Over Bitcoin Complexity – Cointelegraph

Posted on by

Despite being over a decade old, Bitcoin (BTC) is still not particularly easy to understand. Even major BTC bulls like Tim Draper have admitted that Bitcoin still lacks ease of use for mainstream adoption.

In the same vein, two key figures in the community held an informal Twitter debate over Bitcoins complexity today.

Mark Cuban, one of the most well-known Bitcoin sceptics, prefers to own bananas than invest in bitcoins. Cuban previously criticized Bitcoins complexity in an interview with Anthony Pomp Pompliano on April 15. In the interview, the owner of the NBAs Dallas Mavericks reiterated a common Bitcoin complexity narrative, arguing that Bitcoin needs to be easy enough that grandma can use it before mass adoption will occur.

When asked about what would have to happen for him to change his mind about Bitcoin, Cuban answered that it should become easy, elaborating on Bitcoins complexities:

Itd have to be so easy to use, its a no-brainer. Itd have to be completely friction-free and understandable by everybody first. [...] Theres so many peculiarities to Bitcoin: the halving, the mining.

While some in the crypto community agreed that BTC is quite difficult to use, Tyler Winklevoss, a co-founder of major crypto exchange Gemini, decided to weigh in. Winklevoss argued that, for someone without preexisting knowledge of the game, basketball is at least as peculiar as Bitcoin. He tweeted:

Theres so many peculiarities to Bitcoin: the halving, the mining." - @mcuban The rules of basketball are far more peculiar, but that doesn't seem to be holding it back.

It was not long before Cuban reacted to the Winklevoss remark, tweeting the following counter-argument in less than 10 minutes:

One was started by a guy named James in a gym with a peach basket and a ball to entertain kids. The other was started by a guy no one can find, that hundreds claim to be, with a computer and an algorithm to give millions something to argue about. Which is simple?

Winklevoss subsequently argued that both of these origin stories are interesting from a historical perspective,. He then firing out another argument, hinting that nobody really cares about basketball:

My bet is that if you took a poll of all the basketball fans that buy tickets to watch @dallasm games, less than 1% would know that the game they are watching was started by a guy named James trying to entertain kids and 0% would actually care.

After years of scepticism, Cuban delivered a mixed message about Bitcoin in late 2019. As Cointelegraph reported in December, Cuban admitted that Bitcoin could become a reliable financial instrument.

In September 2019, billionaire investor and major Bitcoin bull, Tim Draper, declared that people still prefer fiat money over Bitcoin. He reasoned that fiat money seems to be an easier option to pay for services. According to Draper, Bitcoins inherent difficulty is the main impediment to mass adoption. He further claimed that engineers have not made it that easy enough for everyone to use Bitcoin.

Read the original here:

Mark Cuban and Tyler Winklevoss Squabble Over Bitcoin Complexity - Cointelegraph

Crypto Analyst Cautions Investors Against Bitcoin for 3 Key Reasons – Cointelegraph

Posted on by

Bitcoin is often described as gold 2.0; a superior system of storing and transferring value. It has seen a rapid increase in market capitalization since its introduction in 2009, with strong custodial, exchange, and futures infrastructure.

Yet, one cryptocurrency analyst known as cryptocomicon recently laid out a series of compelling reasons why one should not invest in Bitcon. The three that stood out most were limited privacy, centralized mining, and the lack of scalability.

Despite each of these being valid points to consider, they can also be seen as advantages for BTC.

Up until 2018, governments and various financial bodies criticized the anonymous nature of Bitcoin, stating that it poses a risk to the global financial system. But, as reported by Cointelegraph, South Korea recently cracked down on a large-scale sex crime ring earlier this month through tracking Bitcoin addresses.

One could argue that the lack of privacy measures on the Bitcoin network has actually improved the image of the dominant cryptocurrency.

Previously the public and governments perceived Bitcoin as the currency most preferred for use in criminal activities and terrorist financing, but this view appears to have changed in recent years as sophisticated blockchain analytics companies who offer crypto transaction tracking services emerged.

Following the release of the Financial Action Task Force (FATF)s revised guideline on crypto assets on February 22, 2020, it has become even more challenging to launder money using Bitcoin than ever before.

Thus, the lack of privacy can also be viewed as increased transparency and this could eventually prevent governments from over-regulating Bitcoin-related companies.

The low scalability of Bitcoin is similar to the no privacy argument in the sense that it can be comprehended in two ways: it can make transactions expensive when the network reaches its peak, but it can also encourage second-layer scaling.

Some state that the relatively high fees on the Bitcoin network would push for the use of second-layer scaling solutions, which many believe to be inevitable if public blockchain networks are eventually used by billions of people worldwide.

Other major public blockchain networks with high scalability like Ethereum are exploring second-layer scaling solutions such as plasma, indicating that second-layer scaling is necessary for any large blockchain network.

According to a report from CoinShares Research, up to 65 percent of the Bitcoin network hashpower comes from China, a level unseen since 2017. While the level of mining centralization in China is currently high, over time it is expected to become more distributed across the world.

To date, large mining centers in China have been able to access cheap electricity in mountainous regions of the country, operating ASIC miners at low costs with natural cooling. Consequently, the level of mining centralization in China reached unprecedented levels in December 2019.

Additional data from CoinShares explained that:

While we expect this ratio to fall again as latest generation hardware further makes its way into the non-Chinese market, at the time of writing, as much as 65% of Bitcoin hashpower resides within China the highest weve seen since we began our network monitoring in late 2017.

The researchers also said:

We have reasons to believe the lions share of the newly deployed hardware has been predominantly installed in China. There could be many reasons for this, but Occams Razor suggests that it is likely an effect of relational and geographic proximity to manufacturers making barriers to business comparatively lower.

Chinas Bitcoin mining equipment access and hashrate. Source: CoinShares

Currently Chinas mining sector has two clear advantages over the rest of the world, cheap electricity and direct access to new mining equipment. Eventually, lower electricity rates and better access to newer mining equipment could push the global mining industry to expand outside of China in the years to come, reducing the level of centralization.

More:

Crypto Analyst Cautions Investors Against Bitcoin for 3 Key Reasons - Cointelegraph

Bitcoin: The Halvening Cometh – Forbes

Posted on by

HONG KONG, HONG KONG - NOVEMBER 9: As a visual representation of the digital Cryptocurrency, Bitcoin ... [+] with US Dollar on November 9, 2017 in Hong Kong, Hong Kong. Cryptocurrencies - Bitcoin, have seen unprecedented growth in 2017. (Photo by studioEAST/Getty Images)

Bitcoin remains a controversial asset with most people either believing it as doomed to be valueless or set to be worth $1 million a coin. As such it is probably a fair bet to say it will do neither.

Here is the state of play:

The Bitcoin chart as the 'halvening' approaches

This is what happened last time:

Here's what happened to the Bitcoin price after the last 'halvening'

The idea is that the price will go up because the supply of new coins will halve, so on an even keel basis there will be the same demand but less supply. The increase of bitcoin supply will half but interestingly it will also fall below the recent rate of U.S. dollar inflation. So the thinking goes: supply of new bitcoin down + supply of bitcoin less than U.S. dollars (substantially less since the recent titanic stimulus packages) + ever increasingspread of acceptance = significant price rise.

Doomsters say that miners will flee as they can no longer make money mining and the blockchain will seize up. However, every two weeks the mining difficulty retargets to take that into account, so this scenario simply wont happen and in the end transaction costs would make up for any drop in new coin rewards if the situation became difficult. A $6 per transaction fee would fill the gap, which is super pricey, but not when large transactions are at stake.

The halvening wont break bitcoin, but will it be the beginning of the next leg up?

I think so.

Will it catapult bitcoin to $100,000 a coin? It could happen but I want to believe because I have a pile of bitcoins.

The key factor will be the shape of the developing coronavirus recession. The outcome of these huge stimulus packages are impossible to predict. Not only is their effect utterly unpredictable but even their scale is uncertain. Bitcoin (BTC) is just a tiny sideshow to all these goliath moves.

The only outcome that would hurt BTC is deflationary depression and with trillions of cash being helicoptered in to bailout everyone, at least the deflationary part seems hard to imagine.

What isnt so hard to imagine is something the ex-Federal Reserve Chairman brought up: Hysteresis. Thats not the electrical thing, its the political type. Hysteresis is what Marxists use to explain away the fact that their fabulous theories never seem to be adopted or work. Its a shock to the system that is needed to create the momentum for a sudden and irreversible change. That Ben Benenke should bring up the prospect for that is enough to make your ears burn. Bitcoin $1 million is totally ridiculous but then.

A Zimbabwe one hundred trillion dollar note

Whether hysteresis would mean a trillion dollar bill or something else entirely, it wont do bitcoin any harm.

Love it or hate it, in times of hysteresis a bitcoin wallet would be a prized possession. Even without the halvening, bitcoin looks good as a haven/flight asset in very uncertain times.

-

Clem Chambers is the CEO of private investors websiteADVFN.com and author of 101 Ways to Pick Stock Market Winners and Trading Cryptocurrencies: A Beginners Guide.

Chambers won Journalist of the Year in the Business Market Commentary category in the State Street U.K. Institutional Press Awards in 2018.

Follow this link:

Bitcoin: The Halvening Cometh - Forbes

More Investors Are Holding Bitcoin Ahead of the Halving, Data Suggests – CoinDesk

Posted on by

Investors may be accumulating bitcoin ahead of next month's miner reward halving.

The seven-day moving average of the total number of bitcoin held in exchange addresses fell to 2,214,365 on April 14 the lowest level since last June according to numbers from blockchain intelligence firm Glassnode.

As of Tuesday, the average was down nearly 8 percent from a high of 2,404,786 registered on Jan. 17, 2020.

The decline in exchange balances suggests a shift to longer-term holding strategies, according to Glassnode.

That's because investors usually withdraw coins from the exchanges to hold in their personal wallets when prices are expected to rise. Conversely, they tend to move their balances to exchanges in preparation to sell when a price drop is expected or during a price crash.

For instance, bitcoins price fell by 33 percent in the seven days to March 15. At the time, the seven-day average of coins held on exchanges rose from 2,333,279 on March 11 to 2,350,795 on March 18.

However, the spike was short lived and the downturn in exchange balances resumed from March 19.

The increased levels of holding may be associated with bullish expectations tied to bitcoins mining reward halving, scheduled to take effect in just 27 days. The process, aimed at controlling inflation, will reduce rewards per block mined from 12.5 BTC to 6.25 BTC.

Essentially, miners will be adding fewer coins to the ecosystem following the halving. Some analysts think that would create a supply deficit and push up prices.Once bitcoin has its halving next month, we expect prices to rally, carrying the rest of the market with it, said Richard Rosenblum, head of trading at GSR.

Meanwhile, some stock-to-flow models indicate the halving could send bitcoins price to $100,000, as noted in the cryptocurrency platform Lunos weekly market report.

Further, the coronavirus-induced global economic recession and resulting unprecedented monetary and fiscal stimulus launched by the Federal Reserve and the U.S. government, respectively, are widely expected to boost bitcoins appeal as a safe haven asset and a hedge against inflation.

However, some observers have been skeptical about the bullish narrative surrounding bitcoins halving. Bitcoin halving in May 2020 wont do anything to the price. It will be a non-event, Jason Williams, co-founder of digital asset fund Morgan Creek Digital, tweeted in December.

Meanwhile, the cryptocurrency has so far failed to perform as a safe haven asset and has largely moved in line with the equity markets. Since the beginning of March, bitcoins correlation with the S&P and Dow has been unusually high at approximately 0.82, Nicholas Pelecanos, head of trading at NEM Ventures, told CoinDesk.

If the decline in exchange balances is a guide, though, the investor community looks to have some belief in the bullish halving narrative and the long-term value of the cryptocurrency as an inflation hedge.

From a technical analysis standpoint, the cryptocurrencys recovery rally from the March low of $3,867 looks to have run out of steam.

Weekly chart

Bitcoin has failed three times in the last month to keep gains above the 100-week moving average, currently lined up near $7,060.The repeated failure is suggestive of buyer fatigue.

That, coupled with the rising wedge breakdown seen on the daily chart, suggests scope for a downside break of the recent trading range of $6,600$7,200. A range breakdown, if confirmed, would open the doors to $6,100, as discussed Tuesday.

Bitcoin has enjoyed an over-50-percent rally from its mid-March low. The bulls now must sustain the rally at an equal or greater pace in the short term or the bears might take back some serious ground," said NEM Ventures Pelecanos. "Indicators from one of our momentum-based strategies are beginning to show a serious bearish setup that could lead to a 50-percent sell-off, sending prices into the low $3,000s."

Disclosure:The author currently holds no cryptocurrencies.

The leader in blockchain news, CoinDesk is a media outlet that strives for the highest journalistic standards and abides by a strict set of editorial policies. CoinDesk is an independent operating subsidiary of Digital Currency Group, which invests in cryptocurrencies and blockchain startups.

Continued here:

More Investors Are Holding Bitcoin Ahead of the Halving, Data Suggests - CoinDesk

TOP 3 Bitcoin and Crypto News for Today: 17 April – U.Today

Posted on by

Geoffrey Schwartz

Bitcoin (BTC) price prediction, Binance (BNB) smart chain white paper released, and Nassim Taleb recommends cryptocurrencies.

The last day of the workweek ended in the green for the three major indexes. The Dow Jones Industrial Average (DJIA) rocketed up 704.81 points (about 3%) to close at 24,242.49. The S&P 500 went up 75.01 points (about 2.7%) to close at 2,874.56. The NASDAQ Composite advanced 117.78 points (about 1.4%) to close at 8,650.14. All of this optimism and hope was based on a drug report published by Gilead Sciences, which showed some promise for treating the coronavirus.

As for news within the crypto world, some of the major headlines include a price prediction for Bitcoin (BTC), the release of a Binance (BNB) Smart Chain white paper, and Nassim Taleb recommending the use of cryptocurrencies.

Yesterday morning was strong bullish impulse for the average price of Bitcoin (BTC). As a result, this pushed the BTC/USD pair above the $7,026 mark. By the end of the day, the price of BTC was able to gain a foothold above this support level.

Overnight growth was not supported by large volumes, and a local maximum was set around the $7,224 area. The next morning, the priced rolled back from its maximum.

Looking at the lines from the Stochastic Relative Strength Index (Stoch RSI), the price of BTC is now in the overbought zone. A rollback to the average price region can therefore be expected in the near future. If the 2H EMA55 provides support, then growth may continue to the $7,300 mark.

Yesterdays growth to $7,190 mark closed above $7,000 with a full candle, indicating buyer strength. It is likely not the usual removal of short positions. For the moment, the big picture is an upswing. To confirm this, the bulls need to keep the price above $6,900 and pass the $7,150 resistance level. If that is the case, then traders can expect a significant increase to its previous local maximum of $7,459 or higher.

Binance has broken into the decentralized application market by creating the Binance Smart Chain, a special parallel blockchain to land smart contracts. The Binance Smart Chain, which will be cross-chain interoperable, will use a Proof-of-Stake Authority consensus. As a result, staking the Binance Coin (BNB) will be available to all users.

According to the recently released white paper, the reason a separate chain was required was because:

The execution of a Smart Contract may slow down the exchange function and add non-deterministic factors to trading

While Binance (BNB) is aware of the situation in the dApps market, EOS (EOS), Ethereum (ETH), and Tron (TRX) have managed to address the needs of dApp developers.

With developed countries announcing one stimulus package after another to counteract the effects of the COVID-19 pandemic, some governments are screwing over its citizens. Nassim Nicholas Taleb, author of The Black Swan, highlighted the importance of cryptocurrencies as a tool for cross-border remittances.

According to Pierre Madani, Chief Financial Officer of Kafalat S.A.L., BDL has begun to confiscate hard currencies from over-the-counter remittances because of hyperinflation for the Lebanese Pound (LBP) and the national banks losing credit. Instead of acquiring stable foreign currencies, beneficiaries can only obtain the worthless LBP.

Taleb, a major advocate for Bitcoin (BTC) and other financial institutions involving cryptocurrencies, believes that they could replace the classical remittance and exchange tools in emerging markets. He also applauded the anti-authoritarian nature of Bitcoin (BTC) and other major cryptocurre

See more here:

TOP 3 Bitcoin and Crypto News for Today: 17 April - U.Today